CALLIDITAS NEF 403: Extension Study for IgAN Treatment

This study is for adults with IgA nephropathy (IgAN) who have completed 9 months of TARPEYO® treatment. It aims to see how extended use of TARPEYO® helps manage IgAN and ensure its long-term safety.

Participants will continue treatment for 18 months, with regular check-ups every 3 months. Joining this study helps advance care for IgAN and improve future treatments.